AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AbCellera Biologics reports robust earnings and growth opportunities ahead

AbCellera Biologics demonstrated strong financials and growth in Q4 2022, with a focus on building an engine for antibody discovery and development.
The company's strategic approach to partnerships and contract negotiations provides flexibility and potential for increased value creation.
Despite challenges in decision-making and program advancement, AbCellera's business model and liquidity position position it well for future opportunities.

AbCellera Biologics (ABCL) reports solid Q1 performance and eyes strategic growth opportunities

AbCellera Biologics (ABCL) showcases a strong performance in Q1 2023, focusing on long-term value creation and strategic partnerships.
Despite challenges in revenue streams and resource allocation, the company's emphasis on technology development and program diversity bodes well for future growth.
Opportunities lie in expanding partnerships, leveraging advancements in cancer therapy, and driving innovation in drug development for sustained success.

AbCellera reports Q2 revenue growth, faces clinical development uncertainty

AbCellera Biologics reported mixed financial results for Q2 2023, with revenue growth but a net loss due to continued investments.
The company showcased strengths in patent defense, R&D capabilities, and partnerships, while facing challenges in clinical development uncertainty and financial performance.
Opportunities lie in global therapeutics discovery, liquidity strength, and collaboration with Eli Lilly for COVID-19 antibody development, positioning AbCellera for future growth.

AbCellera reports Q3 results, advances innovative therapies and partnerships

AbCellera Biologics reported mixed financial results in Q3 2023 but demonstrated commitment to advancing innovative therapies and strategic partnerships.
Strengths lie in promising assets, financial stability, innovative molecule design, and progress on development candidates, while challenges include profitability concerns and operational complexities.
Opportunities for growth include expanding the product pipeline, exploring novel treatments through partnerships, and optimizing therapies for improved patient outcomes and market positioning.
Overall, AbCellera's performance reflects a balance of financial stability, innovation, and strategic focus, with future updates poised to drive investor interest and market impact.

AbCellera Biologics reports Q1 performance, highlights partnerships and growth

AbCellera Biologics showcased strong performance in Q1 2024, with a focus on advancing internal programs, strategic partnerships, and technological innovations.
Despite financial challenges, the company's strengths lie in its robust pipeline, strong financial position, and promising partnerships with industry leaders.
Navigating challenges in profitability and market competition, AbCellera has significant opportunities to drive growth through partnerships, technological advancements, and market expansion.

AbCellera Biologics reports Q2 revenue growth and strategic partnerships

AbCellera Biologics' Q2 2024 performance reflects a strong financial position, progress in key programs, and strategic partnerships driving future growth.
While facing challenges in profitability and research fee reductions, the company's focus on innovation and partnerships presents opportunities for market expansion.
Overall, AbCellera's emphasis on internal pipeline development and strategic collaborations positions them well for long-term success in the biologics industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ovid Therapeutics

SIGA Technologies

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on InvestorPlace.

3 Biotech Stocks Under $10 to Add to Your Buy List

AbCellera, the stock, has had a woeful two plus years as a public company; however, AbCellera the business is performing brilliantly. The company recently announced an internally developed T-Cell engager program that it is looking to partner, likely at attractive terms for AbCellera, giving the company another avenue to monetization.

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022

AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AACR22--AbCellera Presents Data on T Cell Engager Platform at AACR 2022

AbCellera Presents Data on T Cell Engager Platform at AACR 2022

Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q4 2021 Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Full Year 2021 Business Results

AbCellera Reports Full Year 2021 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022

AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild to Moderate COVID-19

AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19

AbCellera announced on Thursday Feb 10th a supply deal with the US government and Lilly for Bebtelovimab, the AbCellera developed pan COVID variant antibody treatment.

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Bebtelovimab to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments

Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Changes to Its Board of Directors

AbCellera Announces Changes to Its Board of Directors

AbCellera has been pummeled in the market this year, dropping like a stone to the current price of just over $14 a share. I believe this is a huge mistake. AbCellera currently has 131 programs with royalty agreements under contract and that number continues to grow fast.

AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized for Emergency Use in COVID-19 Patients Under the Age of 12

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q3 2021 Results - Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q3 2021 Business Results

AbCellera Reports Q3 2021 Business Results

The consensus price target hints at a 160.5% upside potential for AbCellera Biologics Inc. (ABCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in AbCellera Biologics Inc. (ABCL)? Wall Street Analysts Think 161%

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Virtual Presentations at Investor Conferences in November

AbCellera Announces Virtual Presentations at Investor Conferences in November

The biotech is now down roughly 56% across 2021's trading.

Why AbCellera Biologics Stock Sank 21.6% in October

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for COVID-19

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19

AbCellera shares have been rocked by news of Merck's "COVID pill" treatment, sending shares down 25% from recent highs. In September, AbCellera's current antibody therapy was put back into use after an FDA pause, giving the company back a key revenue source

AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

Despite last month's gains, the biotech stock is now down roughly 61% year to date.

News for AbCellera Biologics Stock (ABCL)